Relationship between major lab abnormalities and immune checkpoint inhibitors treatment duration; A retrospective single institution study
Latest Information Update: 03 Jun 2019
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
- Indications Bladder cancer; Breast cancer; Cancer; Head and neck cancer; Lung cancer; Lymphoma; Malignant melanoma; Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Jun 2019 New trial record
- 31 May 2019 Results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology